

From: myron.c.harrison@exxonmobil.com
Sent: Tuesday, September 25, 2007 7:00 PM (GMT)
To: Clegg, Patsy M SCC-DCS/22 <patsy.clegg@shell.com>
Cc: alex.yelland@chevron.com; anita.balaraman@chevrontexaco.com;
brian.e.doll@exxonmobil.com; burnetdm@bp.com; Williams, Elizabeth J SCAI-DCS/22
<elizabeth.williams@shell.com>; feldman@api.org; hargettb@api.org;
heroldra@bp.com; hughm7@bp.com; jarnotb@api.org;
jennifer.b.galvin@conocophillips.com; mfitzsimmons@steptoe.com;
michael.g.bird@exxonmobil.com; michael.j.roman@exxonmobil.com;
Mike.d.Johnston@conocophillips.com; Sykes, Paul B SCC-DCS/23
<Paul.Sykes@shell.com>; Snyder, Phil J SDIUS-DXX/9 <phil.snyder@shell.com>;
Colmer, Robert W SC-DCS/18 <Rob.Colmer@shell.com>; Tsai, Shan P SHLOIL-SHS
<Shan.Tsai@shell.com>; stephen.m.bowes@exxonmobil.com; Cagen, Stuart Z
SHLOIL-SHOIL-SHS <stuart.cagen@shell.com>; wagner@api.org; whiter@api.org;
ZachWong@chevrontexaco.com
Subject: Re: Shanghai Health Study - Update to Special Programs Committee - Review and
Comments Requested
Attach: Shanghai Health Study Update - Sept 27 07 with mch comments.doc

Patsy, mostly good news, but a few comments
(See attached file: Shanghai Health Study Update - Sept 27 07 with mch
comments.doc)

Myron Harrison
972.444.1673
<patsy.clegg@shell.com>
To
<hargettb@api.org>,
09/24/2007 <brian.e.doll@exxonmobil.com>,
03:12 PM <jarnotb@api.org>,
<burnetdm@bp.com>,
<feldman@api.org>,
<Mike.d.Johnston@ConocoPhillips.com>
, <whiter@api.org>,
<stuart.cagen@shell.com>,
<ZachWong@chevrontexaco.com>,
<anita.balaraman@chevrontexaco.com>,
<jennifer.b.galvin@conocophillips.com>,
<hughm7@BP.com>,
<michael.g.bird@exxonmobil.com>,
<Shan.Tsai@shell.com>,
<stephen.m.bowes@exxonmobil.com>,
<alex.yelland@chevron.com>,
<Rob.Colmer@shell.com>,
<michael.j.roman@exxonmobil.com>,
<myron.c.harrison@exxonmobil.com>,
<heroldra@bp.com>, <wagner@api.org>,
<mfitzsimmons@steptoe.com>

cc

<elizabeth.williams@shell.com> ,

<Paul.Sykes@shell.com> ,

<phil.snyder@shell.com>

Subject

Shanghai Health Study - Update to
Special Programs Committee - Review
and Comments Requested

Dear Team;

On Thursday, Sept 27, I will be update the API Special Programs Committee on the status of the Shanghai Health Study. I spoke with Brenda Hargett, API staffer that supports the committee, to get briefed on expectations. I do not need a formal presentation; this will be done via teleconference. I have drafted talking points and would appreciate your review and comments - by noon on Wed, Sept 26, please.

<<Shanghai Health Study Update - Sept 27 07.ZIP>>

Patsy Clegg

Product Steward

Shell Chemical LP

One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 Fax: 3325

Email: patsy.clegg@shell.com

Internet: <http://www.shell.com/chemicals>

[attachment "Shanghai Health Study Update - Sept 27 07.ZIP" deleted by
Myron C Harrison/Dallas/ExxonMobil]

Shanghai Health Study – Update to API Special Programs Committee

September 27, 2007

Presented by

Patsy Clegg, Chair Oversight Committee, Benzene Health Research Consortium

Talking Points:

1. All contracts, with the exception of Fudan University and the QA/QC contractor, have been executed.
2. Sufficient funds to support the revised budget have been committed by 4 of the sponsors.
 - Chevron will not be paying any of their committed funds until all contracts are executed.
3. Currently, milestones are being met and payments are being made.
 - One exception is delays in reimbursing Cinpathogen for expenses in excess of \$75 when there is no receipt
 - API is not paying other SHS expenses claiming that these are “Corporate” expenses unrelated to SHS
 - The ongoing nonpayment of these legitimate expenses risks significant adverse consequences for API and the Consortium members
4. The QA/QC process is functioning. A contractor to oversee the process has been identified, but not yet contracted.
5. The time line for the study:
 - June 2007: AML cases stopped being collected.
Test data set transferred to Applied Health Sciences
 - Dec 2007: NHL cases will stop being collected.
 - 2008: Data analysis and publications
 - YE08: Benzene Health Research Consortium will dissolve.
6. API staffers who will be visiting China later this year to open an office in China will visit the study laboratory at Fudan University in Shanghai, although, I believe that Dr. Irons does not know about these plans